| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $14.3M | -60.9% |
| SG&A Expense | $5.8M | -1.1% |
| Operating Income | -$20.1M | +52.7% |
| Income Tax | $0 | — |
| Net Income | -$30.8M | +34.5% |
| EPS (Basic) | -$0.48 | +36.8% |
| EPS (Diluted) | -$0.48 | +36.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $17.7M | +17.2% |
| Current Assets | $19.4M | +12.7% |
| Total Assets | $19.5M | +11.6% |
| Current Liabilities | $8.0M | -77.3% |
| Total Liabilities | $145.7M | +20.9% |
| Stockholders' Equity | -$127.9M | -22.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$23.9M | +42.8% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $26.5M | -15.2% |